William Blair Reiterates Market Perform Rating for Certara (NASDAQ:CERT)

Certara (NASDAQ:CERT)‘s stock had its “market perform” rating reissued by stock analysts at William Blair in a report issued on Thursday,RTT News reports.

A number of other equities analysts also recently weighed in on the company. TD Cowen initiated coverage on Certara in a research report on Thursday. They set a “buy” rating and a $16.00 price target on the stock. Barclays decreased their target price on Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday, November 7th. Stephens reaffirmed an “overweight” rating and set a $17.00 price target on shares of Certara in a report on Thursday. Finally, Robert W. Baird reduced their price objective on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research report on Tuesday, November 5th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $15.79.

Certara Stock Performance

Shares of CERT opened at $11.98 on Thursday. The company has a market cap of $1.93 billion, a PE ratio of -59.90, a price-to-earnings-growth ratio of 9.29 and a beta of 1.57. The firm has a 50-day moving average of $12.45 and a 200-day moving average of $11.64. Certara has a one year low of $9.41 and a one year high of $19.87. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86.

Hedge Funds Weigh In On Certara

Several institutional investors and hedge funds have recently modified their holdings of the business. Venturi Wealth Management LLC boosted its holdings in Certara by 839.1% in the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock valued at $30,000 after purchasing an additional 2,509 shares during the period. Wells Fargo & Company MN increased its holdings in shares of Certara by 48.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock worth $34,000 after purchasing an additional 1,047 shares during the period. Blue Trust Inc. raised its position in shares of Certara by 112.3% in the third quarter. Blue Trust Inc. now owns 3,925 shares of the company’s stock valued at $46,000 after buying an additional 2,076 shares in the last quarter. Johnson Financial Group Inc. bought a new stake in shares of Certara in the fourth quarter valued at approximately $47,000. Finally, KBC Group NV grew its position in Certara by 48.2% during the third quarter. KBC Group NV now owns 4,873 shares of the company’s stock worth $57,000 after buying an additional 1,584 shares in the last quarter. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.